Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Shareholders of Agregat approved dividends for 2023

6/4/24 AGRT

Shareholders of Europlan approved dividends for 2023

6/4/24 LEAS

Find the Job has opened a round of investment raising

6/3/24 OTCI

RusHydro to commission 2.4 GW of power capacity by 2028

6/3/24 HYDR

TMK cancels SPO due to unfavorable market conditions

6/3/24 TRMK

Board of Directors of Abrau-Durso recommended that dividends be paid for 2023

6/3/24 ABRD

Shareholders of Krasnoyarskenergosbyt approved dividends for 2023

6/3/24 KRSB

MCosmetic has agreed a partnership with pharmacy chain OXYmed

6/3/24 MGNT

Yandex is developing a unified neural network for speech and text

6/3/24 YDEX

Sitronics KT to begin mass deployment of unmanned ship navigation technology in 2025

6/3/24 AFKS